FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant's Biz Strategy

Roivant Sciences subsidiary Priovant Therapeutics received FDA approval for brepocitinib (Lisraya), the first targeted treatment for dermatomyositis, a rare inflammatory disease affecting skin and muscles. The drug, a dual JAK1 and TYK2 inhibitor, represents a novel therapy with Phase 3 data showing clinical benefit and comes with a black box warning consistent with its class.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.